FR2832716B1 - Proteine de fusion ayant augmente l'activite in vivo de l'erythroproietine - Google Patents
Proteine de fusion ayant augmente l'activite in vivo de l'erythroproietineInfo
- Publication number
- FR2832716B1 FR2832716B1 FR0209867A FR0209867A FR2832716B1 FR 2832716 B1 FR2832716 B1 FR 2832716B1 FR 0209867 A FR0209867 A FR 0209867A FR 0209867 A FR0209867 A FR 0209867A FR 2832716 B1 FR2832716 B1 FR 2832716B1
- Authority
- FR
- France
- Prior art keywords
- fusion protein
- erythroproietin
- increased
- vivo activity
- carboxy terminal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000000694 effects Effects 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 101800005309 Carboxy-terminal peptide Proteins 0.000 abstract 2
- 102000036693 Thrombopoietin Human genes 0.000 abstract 2
- 108010041111 Thrombopoietin Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000003951 Erythropoietin Human genes 0.000 abstract 1
- 108090000394 Erythropoietin Proteins 0.000 abstract 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 abstract 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 abstract 1
- 230000000567 anti-anemic effect Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 210000003743 erythrocyte Anatomy 0.000 abstract 1
- 229940105423 erythropoietin Drugs 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 102000044890 human EPO Human genes 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2001-0074975A KR100467750B1 (ko) | 2001-11-29 | 2001-11-29 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2832716A1 FR2832716A1 (fr) | 2003-05-30 |
| FR2832716B1 true FR2832716B1 (fr) | 2004-12-03 |
Family
ID=36821313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR0209867A Expired - Lifetime FR2832716B1 (fr) | 2001-11-29 | 2002-08-02 | Proteine de fusion ayant augmente l'activite in vivo de l'erythroproietine |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7098318B2 (fr) |
| EP (1) | EP1319712B1 (fr) |
| JP (1) | JP3860097B2 (fr) |
| KR (1) | KR100467750B1 (fr) |
| CN (1) | CN100390201C (fr) |
| AR (1) | AR036384A1 (fr) |
| AT (1) | ATE460483T1 (fr) |
| AU (1) | AU2002300359B2 (fr) |
| BR (1) | BRPI0203394B1 (fr) |
| CA (1) | CA2394572C (fr) |
| DE (2) | DE10235248B4 (fr) |
| ES (1) | ES2339426T3 (fr) |
| FR (1) | FR2832716B1 (fr) |
| GB (1) | GB2382580B (fr) |
| IT (1) | ITMI20021803A1 (fr) |
| MX (1) | MXPA02008131A (fr) |
| MY (1) | MY122935A (fr) |
| NZ (1) | NZ520442A (fr) |
| RU (1) | RU2225220C1 (fr) |
| SG (1) | SG117416A1 (fr) |
| TW (1) | TWI237056B (fr) |
| WO (1) | WO2003046013A1 (fr) |
| ZA (1) | ZA200206172B (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7345019B1 (en) * | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| CN1897959A (zh) * | 2003-09-29 | 2007-01-17 | 沃伦药品公司 | 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子 |
| US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US7553940B2 (en) * | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting EPO polypeptides and derivatives thereof and methods thereof |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8067548B2 (en) | 2007-07-26 | 2011-11-29 | Novagen Holding Corporation | Fusion proteins having mutated immunoglobulin hinge region |
| CN101863982A (zh) * | 2009-04-17 | 2010-10-20 | 哈药集团生物工程有限公司 | 一种用于升高血小板的融合蛋白及其制备方法 |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| CN103864913A (zh) * | 2012-12-18 | 2014-06-18 | 联亚生技开发股份有限公司 | 重组蛋白 |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| WO2016203482A2 (fr) | 2015-06-19 | 2016-12-22 | Opko Biologics Ltd. | Facteurs de coagulation à action prolongée et leurs procédés de production |
| BR112019000610A2 (pt) | 2016-07-11 | 2019-07-02 | Opko Biologics Ltd | fator vii de coagulação de longa ação e métodos de produção do mesmo |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2053864C (fr) * | 1989-02-21 | 2001-11-20 | Irving Boime | Formes modifiees d'hormones de reproduction |
| WO1990012877A1 (fr) * | 1989-04-19 | 1990-11-01 | Cetus Corporation | Proteines m-csf multifonctionnelles et codage de genes pour celles-ci |
| US5856298A (en) * | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
| CN1057534C (zh) * | 1993-08-17 | 2000-10-18 | 柯瑞英-艾格公司 | 促红细胞生成素类似物 |
| SG47030A1 (en) * | 1994-01-03 | 1998-03-20 | Genentech Inc | Thrombopoietin |
| ITFI940106A1 (it) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
| WO1996023888A1 (fr) * | 1995-02-03 | 1996-08-08 | G.D. Searle & Co. | NOUVEAUX LIGANDS SE FIXANT A c-MPL |
| AU8182298A (en) * | 1997-07-10 | 1999-02-08 | Beth Israel Deaconess Medical Center | Recombinant erythropoietin / immunoglobulin fusion proteins |
| US6242570B1 (en) * | 1997-07-10 | 2001-06-05 | Beth Israel Deaconess Medical Center | Production and use of recombinant protein multimers with increased biological activity |
| DE69838552T2 (de) * | 1997-07-14 | 2008-05-21 | Bolder Biotechnology, Inc., Louisville | Derivate des wachstumshormons und verwandte proteine |
| US6342220B1 (en) * | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| AU3538799A (en) * | 1998-04-30 | 1999-11-23 | Kirin Brewery Company, Limited | Human thrombopoietin mutants |
| JP4944324B2 (ja) * | 1999-07-13 | 2012-05-30 | ボルダー バイオテクノロジー， インコーポレイテッド | 免疫グロブリン融合タンパク質 |
| CA2391080A1 (fr) * | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Formes d'erythropoietine dotees de proprietes ameliorees |
-
2001
- 2001-11-29 KR KR10-2001-0074975A patent/KR100467750B1/ko not_active IP Right Cessation
-
2002
- 2002-07-24 CA CA002394572A patent/CA2394572C/fr not_active Expired - Fee Related
- 2002-07-26 WO PCT/KR2002/001420 patent/WO2003046013A1/fr active Search and Examination
- 2002-07-26 TW TW091116686A patent/TWI237056B/zh not_active IP Right Cessation
- 2002-07-30 MY MYPI20022857A patent/MY122935A/en unknown
- 2002-07-30 NZ NZ520442A patent/NZ520442A/en not_active IP Right Cessation
- 2002-07-30 AU AU2002300359A patent/AU2002300359B2/en not_active Ceased
- 2002-08-01 EP EP02016953A patent/EP1319712B1/fr not_active Expired - Lifetime
- 2002-08-01 DE DE10235248A patent/DE10235248B4/de not_active Expired - Fee Related
- 2002-08-01 ES ES02016953T patent/ES2339426T3/es not_active Expired - Lifetime
- 2002-08-01 DE DE60235603T patent/DE60235603D1/de not_active Expired - Lifetime
- 2002-08-01 SG SG200204673A patent/SG117416A1/en unknown
- 2002-08-01 AT AT02016953T patent/ATE460483T1/de active
- 2002-08-02 FR FR0209867A patent/FR2832716B1/fr not_active Expired - Lifetime
- 2002-08-02 ZA ZA200206172A patent/ZA200206172B/xx unknown
- 2002-08-06 GB GB0218252A patent/GB2382580B/en not_active Expired - Fee Related
- 2002-08-08 IT IT001803A patent/ITMI20021803A1/it unknown
- 2002-08-20 BR BRPI0203394A patent/BRPI0203394B1/pt not_active IP Right Cessation
- 2002-08-21 MX MXPA02008131A patent/MXPA02008131A/es active IP Right Grant
- 2002-08-23 CN CNB021301557A patent/CN100390201C/zh not_active Expired - Fee Related
- 2002-08-29 US US10/230,454 patent/US7098318B2/en active Active
- 2002-08-30 RU RU2002123438/15A patent/RU2225220C1/ru not_active IP Right Cessation
- 2002-08-30 JP JP2002253938A patent/JP3860097B2/ja not_active Expired - Fee Related
- 2002-08-30 AR ARP020103279A patent/AR036384A1/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2832716B1 (fr) | Proteine de fusion ayant augmente l'activite in vivo de l'erythroproietine | |
| EP2189475A3 (fr) | Polypeptides de type facteur de croissance des fibroblastes | |
| ATE319827T1 (de) | Polypeptid, das die differenzierung unterdrueckt | |
| EP2277888A3 (fr) | Protéine chimérique d'albumine et érythropoïetine | |
| WO2004110472A3 (fr) | Proteines de fusion | |
| EP1832599A3 (fr) | Proteines de fusion d'albumine | |
| AU2001254624A1 (en) | Human coagulation factor vii variants | |
| EP1450751A4 (fr) | Vehicule d'administration de nanoparticules | |
| AU2001278797A1 (en) | Expression vector using for animal cell | |
| ATE333893T1 (de) | Gentherapie für gaucher-krankheit | |
| MXPA03001984A (es) | Variantes de factor vii de coagulacion humano. | |
| WO1999040197A3 (fr) | Variants du facteur angiogenique de croissance cellulaire endotheliale vasculaire vegf | |
| AU2002330215A1 (en) | Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease | |
| HUP0500637A2 (hu) | Neublasztin polimer konjugátumai és alkalmazási eljárásai | |
| BR0000698A (pt) | 15, 15'-dioxigenases de beta, beta-caroteno | |
| WO2000008157A3 (fr) | Genes humains transporteurs d'anions atnov | |
| FR2764303B1 (fr) | Proteine a activite d'aspartase, adn la codant, plasmide contenant l'adn et procede de production de la proteine et d'acide l-aspartique | |
| ATE420179T1 (de) | Identifizierung des plasmodium falciparum erythrozyt membranprotein 1 (pfemp1) gebietes, das adhäsion zum chondroitin sulfat a vermittelt | |
| AU2001233957A1 (en) | Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depression | |
| WO1999058098A8 (fr) | Antithrombines iii humaines et procedes connexes | |
| AU2912300A (en) | Peroxochloric acid, derivatives and anions, salts thereof, method for producing them and use of the same | |
| DE60030621D1 (de) | DNA-Konstrukt zur gewebespezifischen Expression eines Blutkgerinnungsfaktors | |
| DE60336596D1 (de) | Ortspezifische verabreichung von aktiven substanzen im darm | |
| WO2005049818A3 (fr) | Gene | |
| WO1999036440A3 (fr) | Expression de proteines hybrides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property | ||
| TP | Transmission of property |
Owner name: CJ HEALTHCARE CORPORATION, KR Effective date: 20141209 |
|
| PLFP | Fee payment |
Year of fee payment: 15 |
|
| PLFP | Fee payment |
Year of fee payment: 16 |